ArticleNPJ breast cancer2022

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.

Lisa A Carey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.